Aperon Biosystems Corp.
This article was originally published in Start Up
Executive Summary
Aperon Biosystems Corp. wants to make monitoring of nitric oxide-a reliable marker of airway inflammation--as routine for asthma patients as glucose checks are for diabetics. It is developing a low cost, noninvasive NO biosensor suitable for use at the point of care and at home for asthma self management. The company believes that regular monitoring with its device will give patients the feedback they need to better control their symptoms.
You may also be interested in...
Start-Up News October 2006
Arbios Systems and Livercyte provide assistance for the failing liver, and Aperon Biosystems takes up the asthma challenge.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.